DAWN Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-10 | Blackman Samuel C. | officer: Chief Medical Officer | 1,233,660 | S-Sale | D | 10,000 | 18.05 | 180,484.00 |
| 2023-03-07 | Bender Jeremy | director, officer: Chief Executive Officer | 1,174,276 | S-Sale | D | 12,500 | 20.01 | 250,113.75 |
| 2023-03-01 | Grant Julie Papanek | director | 330,000 | S-Sale | D | 25,000 | 18.61 | 465,302.50 |
| 2023-02-17 | York Charles N II | officer: COO, CFO and Secretary | 262,128 | S-Sale | D | 9,377 | 20.03 | 187,790.37 |
| 2023-02-16 | York Charles N II | officer: COO, CFO and Secretary | 271,505 | S-Sale | D | 930 | 19.57 | 18,202.89 |
| 2023-02-16 | Bender Jeremy | director, officer: Chief Executive Officer | 1,186,776 | S-Sale | D | 3,022 | 19.57 | 59,149.61 |
| 2023-02-16 | Blackman Samuel C. | officer: Chief Medical Officer | 1,243,660 | S-Sale | D | 674 | 19.57 | 13,192.20 |
| 2023-02-15 | York Charles N II | officer: COO, CFO and Secretary | 33,750 | M-Exempt | D | 2,250 | 0.00 | 0.00 |
| 2023-02-15 | York Charles N II | officer: COO, CFO and Secretary | 15,125 | M-Exempt | D | 1,375 | 0.00 | 0.00 |
| 2023-02-15 | York Charles N II | officer: COO, CFO and Secretary | 272,435 | M-Exempt | A | 2,250 | 0.00 | 0.00 |
| 2023-02-15 | York Charles N II | officer: COO, CFO and Secretary | 270,185 | M-Exempt | A | 1,375 | 0.00 | 0.00 |
| 2023-02-15 | Bender Jeremy | director, officer: Chief Executive Officer | 71,250 | M-Exempt | D | 4,750 | 0.00 | 0.00 |
| 2023-02-15 | Bender Jeremy | director, officer: Chief Executive Officer | 39,190 | M-Exempt | D | 3,562 | 0.00 | 0.00 |
| 2023-02-15 | Bender Jeremy | director, officer: Chief Executive Officer | 1,189,798 | M-Exempt | A | 4,750 | 0.00 | 0.00 |
| 2023-02-15 | Bender Jeremy | director, officer: Chief Executive Officer | 1,185,048 | M-Exempt | A | 3,562 | 0.00 | 0.00 |
| 2023-02-15 | Blackman Samuel C. | officer: Chief Medical Officer | 21,563 | M-Exempt | D | 1,437 | 0.00 | 0.00 |
| 2023-02-15 | Blackman Samuel C. | officer: Chief Medical Officer | 13,065 | M-Exempt | D | 1,187 | 0.00 | 0.00 |
| 2023-02-15 | Blackman Samuel C. | officer: Chief Medical Officer | 1,244,334 | M-Exempt | A | 1,437 | 0.00 | 0.00 |
| 2023-02-15 | Blackman Samuel C. | officer: Chief Medical Officer | 1,242,897 | M-Exempt | A | 1,187 | 0.00 | 0.00 |
| 2023-02-10 | Blackman Samuel C. | officer: Chief Medical Officer | 1,241,710 | S-Sale | D | 10,000 | 20.07 | 200,659.00 |
| 2023-02-01 | Grant Julie Papanek | director | 355,000 | S-Sale | D | 1,106 | 21.69 | 23,988.26 |
| 2023-02-01 | Grant Julie Papanek | director | 356,106 | S-Sale | D | 23,894 | 21.21 | 506,806.08 |
| 2023-01-23 | Bender Jeremy | director, officer: Chief Executive Officer | 1,181,486 | S-Sale | D | 12,500 | 22.00 | 274,987.50 |
| 2023-01-20 | York Charles N II | officer: COO, CFO and Secretary | 268,810 | S-Sale | D | 10,000 | 22.75 | 227,523.00 |
| 2023-01-17 | York Charles N II | officer: COO, CFO and Secretary | 36,000 | A-Award | A | 36,000 | 0.00 | 0.00 |
| 2023-01-17 | York Charles N II | officer: COO, CFO and Secretary | 116,000 | A-Award | A | 116,000 | 20.87 | 2,420,920.00 |
| 2023-01-17 | Blackman Samuel C. | officer: Chief Medical Officer | 23,000 | A-Award | A | 23,000 | 0.00 | 0.00 |
| 2023-01-17 | Blackman Samuel C. | officer: Chief Medical Officer | 72,000 | A-Award | A | 72,000 | 20.87 | 1,502,640.00 |
| 2023-01-17 | Bender Jeremy | director, officer: Chief Executive Officer | 76,000 | A-Award | A | 76,000 | 0.00 | 0.00 |
| 2023-01-17 | Bender Jeremy | director, officer: Chief Executive Officer | 244,000 | A-Award | A | 244,000 | 20.87 | 5,092,280.00 |
| 2023-01-10 | Blackman Samuel C. | officer: Chief Medical Officer | 1,250,148 | S-Sale | D | 2,500 | 23.20 | 58,011.25 |
| 2023-01-10 | Blackman Samuel C. | officer: Chief Medical Officer | 1,252,648 | S-Sale | D | 7,500 | 22.75 | 170,632.50 |
| 2023-01-03 | Grant Julie Papanek | director | 380,000 | S-Sale | D | 7,610 | 21.31 | 162,173.67 |
| 2023-01-03 | Grant Julie Papanek | director | 387,610 | S-Sale | D | 17,390 | 20.36 | 353,973.45 |
| 2022-12-21 | Bender Jeremy | director, officer: Chief Executive Officer | 1,192,424 | S-Sale | D | 12,500 | 20.32 | 253,968.75 |
| 2022-12-20 | York Charles N II | officer: COO, CFO and Secretary | 276,497 | S-Sale | D | 10,000 | 20.07 | 200,650.00 |
| 2022-12-12 | Atlas Venture Fund XI, L.P. | 10 percent owner | 6,008,534 | J-Other | D | 600,854 | 0.00 | 0.00 |
| 2022-12-08 | Grant Julie Papanek | director | 405,000 | S-Sale | D | 4,358 | 22.08 | 96,210.26 |
| 2022-12-02 | Grant Julie Papanek | director | 409,358 | S-Sale | D | 5,000 | 21.55 | 107,726.00 |
| 2022-12-01 | Grant Julie Papanek | director | 414,358 | S-Sale | D | 240 | 22.34 | 5,361.00 |
| 2022-12-01 | Grant Julie Papanek | director | 414,598 | S-Sale | D | 4,760 | 21.72 | 103,393.39 |
| 2022-12-01 | Blackman Samuel C. | officer: Chief Medical Officer | 1,260,148 | S-Sale | D | 900 | 22.16 | 19,940.04 |
| 2022-12-01 | Blackman Samuel C. | officer: Chief Medical Officer | 1,261,048 | S-Sale | D | 9,100 | 21.38 | 194,589.85 |
| 2022-11-21 | Bender Jeremy | director, officer: Chief Executive Officer | 1,204,924 | S-Sale | D | 400 | 21.38 | 8,552.00 |
| 2022-11-21 | Bender Jeremy | director, officer: Chief Executive Officer | 1,205,324 | S-Sale | D | 12,100 | 20.74 | 250,927.38 |
| 2022-11-21 | York Charles N II | officer: COO, CFO and Secretary | 286,497 | S-Sale | D | 300 | 21.39 | 6,417.00 |
| 2022-11-21 | York Charles N II | officer: COO, CFO and Secretary | 286,797 | S-Sale | D | 9,700 | 20.74 | 201,152.78 |
| 2022-11-16 | York Charles N II | officer: COO, CFO and Secretary | 296,497 | S-Sale | D | 430 | 21.46 | 9,227.71 |
| 2022-11-16 | Blackman Samuel C. | officer: Chief Medical Officer | 1,270,148 | S-Sale | D | 377 | 21.46 | 8,090.34 |
| 2022-11-16 | Bender Jeremy | director, officer: Chief Executive Officer | 1,217,424 | S-Sale | D | 1,513 | 21.46 | 32,468.68 |
| 2022-11-15 | York Charles N II | officer: COO, CFO and Secretary | 16,500 | M-Exempt | D | 1,375 | 0.00 | 0.00 |
| 2022-11-15 | York Charles N II | officer: COO, CFO and Secretary | 295,776 | M-Exempt | A | 1,375 | 0.00 | 0.00 |
| 2022-11-15 | Blackman Samuel C. | officer: Chief Medical Officer | 14,252 | M-Exempt | D | 1,187 | 0.00 | 0.00 |
| 2022-11-15 | Blackman Samuel C. | officer: Chief Medical Officer | 1,270,525 | M-Exempt | A | 1,187 | 0.00 | 0.00 |
| 2022-11-15 | Bender Jeremy | director, officer: Chief Executive Officer | 42,752 | M-Exempt | D | 3,562 | 0.00 | 0.00 |
| 2022-11-15 | Bender Jeremy | director, officer: Chief Executive Officer | 1,218,937 | M-Exempt | A | 3,562 | 0.00 | 0.00 |
| 2022-11-02 | Grant Julie Papanek | director | 419,358 | S-Sale | D | 5,000 | 20.01 | 100,069.00 |
| 2022-11-01 | York Charles N II | officer: COO, CFO and Secretary | 294,401 | S-Sale | D | 10,000 | 20.03 | 200,313.00 |
| 2022-11-01 | Grant Julie Papanek | director | 424,358 | S-Sale | D | 5,000 | 20.04 | 100,208.50 |
| 2022-11-01 | Blackman Samuel C. | officer: Chief Medical Officer | 1,269,338 | S-Sale | D | 10,000 | 20.01 | 200,050.00 |
| 2022-11-01 | Bender Jeremy | director, officer: Chief Executive Officer | 1,215,375 | S-Sale | D | 12,500 | 20.03 | 250,355.00 |
| 2022-10-04 | Grant Julie Papanek | director | 429,358 | S-Sale | D | 5,000 | 20.00 | 100,000.00 |
| 2022-10-03 | York Charles N II | officer: COO, CFO and Secretary | 304,401 | S-Sale | D | 10,000 | 20.05 | 200,473.00 |
| 2022-10-03 | Grant Julie Papanek | director | 434,358 | S-Sale | D | 5,000 | 20.06 | 100,315.00 |
| 2022-10-03 | Bender Jeremy | director, officer: Chief Executive Officer | 1,227,875 | S-Sale | D | 12,500 | 20.05 | 250,646.25 |
| 2022-10-03 | Blackman Samuel C. | officer: Chief Medical Officer | 1,279,338 | S-Sale | D | 10,000 | 19.99 | 199,852.00 |
| 2022-09-21 | Grant Julie Papanek | director | 6,964,301 | J-Other | D | 1,500,000 | 0.00 | 0.00 |
| 2022-09-21 | Grant Julie Papanek | director | 8,464,301 | S-Sale | D | 6,106 | 19.29 | 117,784.74 |
| 2022-09-21 | Grant Julie Papanek | director | 8,470,407 | S-Sale | D | 607,497 | 18.54 | 11,262,994.38 |
| 2022-09-21 | Canaan XI L.P. | 10 percent owner | 6,964,301 | J-Other | D | 1,500,000 | 0.00 | 0.00 |
| 2022-09-21 | Canaan XI L.P. | 10 percent owner | 8,464,301 | S-Sale | D | 6,106 | 19.29 | 117,784.74 |
| 2022-09-21 | Canaan XI L.P. | 10 percent owner | 8,470,407 | S-Sale | D | 607,497 | 18.54 | 11,262,994.38 |
| 2022-09-20 | Grant Julie Papanek | director | 9,077,904 | S-Sale | D | 2,266 | 20.10 | 45,546.60 |
| 2022-09-20 | Grant Julie Papanek | director | 9,080,170 | S-Sale | D | 146,404 | 19.50 | 2,854,878.00 |
| 2022-09-20 | Canaan XI L.P. | 10 percent owner | 9,077,904 | S-Sale | D | 2,266 | 20.10 | 45,546.60 |
| 2022-09-20 | Canaan XI L.P. | 10 percent owner | 9,080,170 | S-Sale | D | 146,404 | 19.50 | 2,854,878.00 |
| 2022-09-19 | Atlas Venture Fund XI, L.P. | 10 percent owner | 6,609,388 | J-Other | D | 600,854 | 0.00 | 0.00 |
| 2022-09-19 | Grant Julie Papanek | director | 9,226,574 | S-Sale | D | 76,725 | 20.57 | 1,578,233.25 |
| 2022-09-19 | Canaan XI L.P. | 10 percent owner | 9,226,574 | S-Sale | D | 76,725 | 20.57 | 1,578,233.25 |
| 2022-09-16 | Grant Julie Papanek | director | 9,303,299 | S-Sale | D | 3,722 | 22.04 | 82,032.88 |
| 2022-09-16 | Grant Julie Papanek | director | 9,307,021 | S-Sale | D | 111,585 | 21.53 | 2,402,425.05 |
| 2022-09-16 | Canaan XI L.P. | 10 percent owner | 9,303,299 | S-Sale | D | 3,722 | 22.04 | 82,032.88 |
| 2022-09-16 | Canaan XI L.P. | 10 percent owner | 9,307,021 | S-Sale | D | 111,585 | 21.53 | 2,402,425.05 |
| 2022-09-15 | Grant Julie Papanek | director | 9,418,606 | S-Sale | D | 3,314 | 23.73 | 78,641.22 |
| 2022-09-15 | Grant Julie Papanek | director | 9,421,920 | S-Sale | D | 47,967 | 22.79 | 1,093,167.93 |
| 2022-09-15 | Canaan XI L.P. | 10 percent owner | 9,418,606 | S-Sale | D | 3,314 | 23.73 | 78,641.22 |
| 2022-09-15 | Canaan XI L.P. | 10 percent owner | 9,421,920 | S-Sale | D | 47,967 | 22.79 | 1,093,167.93 |
| 2022-09-14 | Grant Julie Papanek | director | 9,469,887 | S-Sale | D | 384 | 24.29 | 9,327.36 |
| 2022-09-14 | Grant Julie Papanek | director | 9,470,271 | S-Sale | D | 105,727 | 23.68 | 2,503,615.36 |
| 2022-09-14 | Canaan XI L.P. | 10 percent owner | 9,469,887 | S-Sale | D | 384 | 24.29 | 9,327.36 |
| 2022-09-14 | Canaan XI L.P. | 10 percent owner | 9,470,271 | S-Sale | D | 105,727 | 23.68 | 2,503,615.36 |
| 2022-09-13 | Grant Julie Papanek | director | 9,575,998 | S-Sale | D | 1,003 | 25.01 | 25,085.03 |
| 2022-09-13 | Grant Julie Papanek | director | 9,577,001 | S-Sale | D | 86,644 | 24.39 | 2,113,247.16 |
| 2022-09-13 | Canaan XI L.P. | 10 percent owner | 9,575,998 | S-Sale | D | 1,003 | 25.01 | 25,085.03 |
| 2022-09-13 | Canaan XI L.P. | 10 percent owner | 9,577,001 | S-Sale | D | 86,644 | 24.39 | 2,113,247.16 |
| 2022-09-12 | Nicholson Garry A | director | 33,900 | A-Award | A | 33,900 | 25.84 | 875,976.00 |
| 2022-09-02 | Grant Papanek Julie | director | 439,358 | S-Sale | D | 5,000 | 23.82 | 119,107.50 |
| 2022-09-01 | Bender Jeremy | director, officer: Chief Executive Officer | 1,240,375 | S-Sale | D | 1,859 | 23.79 | 44,226.54 |
| 2022-09-01 | Bender Jeremy | director, officer: Chief Executive Officer | 1,242,234 | S-Sale | D | 10,641 | 23.15 | 246,354.05 |
| 2022-09-01 | York Charles N II | officer: COO, CFO and Secretary | 314,401 | S-Sale | D | 1,394 | 23.80 | 33,175.39 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.